Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Language
English
Source: News from NEI - Category: Opthalmology Authors: Jason Source Type: news
More News: Avastin | Clinical Trials | Diabetes | Endocrinology | Eyes | Health | Lucentis | Opthalmology | Ranibizumab Injection